Clinical Trials Logo

Cryoglobulinemia clinical trials

View clinical trials related to Cryoglobulinemia.

Filter by:

NCT ID: NCT02556866 Terminated - Systemic Vasculitis Clinical Trials

Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis

ESBAM
Start date: July 17, 2015
Phase: Phase 2
Study type: Interventional

Multicenter randomized double-blind study comparing the efficacy and safety of rituximab in combination with corticosteroids to corticosteroids plus placebo in the treatment of non-infectious active mixed cryoglobulinemia vasculitis.

NCT ID: NCT00960713 Completed - Pemphigus Clinical Trials

The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders

RITAI
Start date: June 2009
Phase: N/A
Study type: Observational

The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for various auto-immune diseases.

NCT ID: NCT00574652 Completed - Clinical trials for Cryoglobulinemia Vasculitis

Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients

Start date: March 2008
Phase: Phase 1/Phase 2
Study type: Interventional

A systemic Vasculitis is found in 5 to 10% of HCV infected patients with mixed cryoglobulinemia (MC). It mainly involves the skin, peripheral nerve and the kidney and may be life threatening. Twenty to 30% of HCV-MC Vasculitis patients are resistant to conventional therapy (i.e. antiviral therapy and/or immunosuppressors) and still have an active disease. Thus, new therapeutic approaches are necessary in such patients. We recently described a regulatory T cell (Treg) deficiency in HCV-related Vasculitis patients. Immunomodulatory effects of interleukin-2 (IL-2) are well established, notably the preferential expansion of Treg able to suppress inflammatory responses mediated by CD4+ and CD8+ T cells.